window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 7, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

EMA

  • Advanced Therapies,Clinical & Regulatory,Therapeutic Areas

    EMA grants orphan drug designation to Kedrion treatment for congenital aceruloplasminemia

    Kedrion has received orphan drug designation from the European Medicines [...]

    May 5, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Otsuka submits EMA application for Inaqovi and venetoclax combination to treat acute myeloid leukaemia

    Otsuka Pharmaceutical Europe has submitted a marketing authorisation application (MAA) [...]

    May 5, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Tezspire recommended for EU approval for chronic rhinosinusitis with nasal polyps

    AstraZeneca and Amgen’s Tezspire (tezepelumab) has received a positive opinion [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Opinion & Events,Pharmaceuticals and therapeutics

    MaaT Pharma reports strong Phase 3 results and EMA submission for Xervyteg

    MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotech focused on microbiome-based [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    SOM Biotech secures EMA orphan designation opinion for Huntington’s drug SOM3355

    Barcelona-based biotech advances Huntington’s programme as EMA backs orphan designation, [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Opinion & Events,Therapeutic Areas

    CHMP backs Gilead’s twice-yearly lenacapavir for HIV prevention under accelerated EMA review

    Gilead Sciences has received a positive opinion from the Committee [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Manufacturing & Supply Chain

    Is Europe rising? How global pharma uncertainty is fuelling a new era for European innovation

    As global pharma grapples with shifting regulations, rising geopolitical tensions, [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development

    MaaT Pharma submits EMA application for Xervyteg in graft-versus-host disease

    MaaT Pharma has submitted a marketing authorisation application (MAA) to [...]

    May 5, 2026
  • Digital & Data,Drug Discovery & Development,Opinion & Events

    AI governance in pharmacovigilance: Marie Flanagan calls for safety-specific frameworks to safeguard patient risk

    The integration of artificial intelligence into pharmacovigilance is prompting a [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development

    New study urges EU to overhaul regulatory landscape to remain competitive in pharma innovation

    Research from Bayes Business School and Merck KGaA identifies barriers [...]

    May 5, 2026
Previous12

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • How AI is reshaping clinical trials: Saama on the next phase of regulated AI
    Categories: Clinical & Regulatory, Digital & Data, Drug Discovery & Development, Research & Development
  • MRI study suggests some prostate cancer biopsies could eventually be avoided
    Categories: Clinical & Regulatory, Medical devices, Research & Development, Therapeutic Areas
  • START and Allegheny Health Network to expand access to early-phase cancer trials
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top